Rising Prevalence of Chronic Kidney Disease Driving Demand
The Erythropoietin Drugs Market is experiencing steady growth due to the rising global burden of chronic kidney disease (CKD). CKD patients often suffer from anemia, which significantly impacts their quality of life. Erythropoietin therapy helps restore hemoglobin levels, reducing fatigue and improving overall well-being.
With CKD rates increasing due to aging populations, diabetes, and hypertension, demand for erythropoietin treatments is expected to climb further. Governments and healthcare providers are prioritizing early diagnosis and management, which includes integrating erythropoietin drugs into treatment guidelines for better patient outcomes.
2 Views